Literature DB >> 29788359

Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease: A Matched-case Control Pilot Study.

Jung H Suh1, Émilie Degagné1, Elizabeth E Gleghorn1, Mala Setty1, Alexis Rodriguez2, K T Park2, Sofia G Verstraete3, Melvin B Heyman3, Ashish S Patel4, Melissa Irek4, Ginny L Gildengorin1, Neil E Hubbard5, Alexander D Borowsky5, Julie D Saba1.   

Abstract

Goal: The aim of this study was to investigate gene expression levels of proteins involved in sphingosine-1-phosphate (S1P) metabolism and signaling in a pediatric inflammatory bowel disease (IBD) patient population. Background: IBD is a debilitating disease affecting 0.4% of the US population. The incidence of IBD in childhood is rising. Identifying effective targeted therapies that can be used safely in young patients and developing tools for selecting specific candidates for targeted therapies are important goals. Clinical IBD trials now underway target S1PR1, a receptor for the pro-inflammatory sphingolipid S1P. However, circulating and tissue sphingolipid levels and S1P-related gene expression have not been characterized in pediatric IBD.
Methods: Pediatric IBD patients and controls were recruited in a four-site study. Patients received a clinical score using PUCAI or PCDAI evaluation. Colon biopsies were collected during endoscopy. Gene expression was measured by qRT-PCR. Plasma and gut tissue sphingolipids were measured by LC-MS/MS.
Results: Genes of S1P synthesis (SPHK1, SPHK2), degradation (SGPL1), and signaling (S1PR1, S1PR2, and S1PR4) were significantly upregulated in colon biopsies of IBD patients with moderate/severe symptoms compared with controls or patients in remission. Tissue ceramide, dihydroceramide, and ceramide-1-phosphate (C1P) levels were significantly elevated in IBD patients compared with controls. Conclusions: A signature of elevated S1P-related gene expression in colon tissues of pediatric IBD patients correlates with active disease and normalizes in remission. Biopsied gut tissue from symptomatic IBD patients contains high levels of pro-apoptotic and pro-inflammatory sphingolipids. A combined analysis of gut tissue sphingolipid profiles with this S1P-related gene signature may be useful for monitoring response to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29788359      PMCID: PMC5986285          DOI: 10.1093/ibd/izy007

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  51 in total

1.  Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor.

Authors:  Thierry Walzer; Laura Chiossone; Julie Chaix; Andrew Calver; Claude Carozzo; Laure Garrigue-Antar; Yannick Jacques; Myriam Baratin; Elena Tomasello; Eric Vivier
Journal:  Nat Immunol       Date:  2007-10-28       Impact factor: 25.606

2.  Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.

Authors:  Jeffrey Hyams; James Markowitz; Anthony Otley; Joel Rosh; David Mack; Athos Bousvaros; Subra Kugathasan; M Pfefferkorn; Vasundhara Tolia; Jonathan Evans; William Treem; Robert Wyllie; Robert Rothbaum; J del Rosario; Aubrey Katz; Adam Mezoff; M Oliva-Hemker; Trudy Lerer; Anne Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-10       Impact factor: 2.839

3.  Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Jacek Bielawski; Zdzislaw M Szulc; Yusuf A Hannun; Alicja Bielawska
Journal:  Methods       Date:  2006-06       Impact factor: 3.608

4.  FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.

Authors:  R Fujii; T Kanai; Y Nemoto; S Makita; S Oshima; R Okamoto; K Tsuchiya; T Totsuka; M Watanabe
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-03-30       Impact factor: 4.052

5.  The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.

Authors:  Yasuyuki Deguchi; Akira Andoh; Yuki Yagi; Shigeki Bamba; Osamu Inatomi; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  Oncol Rep       Date:  2006-10       Impact factor: 3.906

6.  Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis.

Authors:  Debby Laukens; Michel Georges; Cécile Libioulle; Cynthia Sandor; Myriam Mni; Bert Vander Cruyssen; Harald Peeters; Dirk Elewaut; Martine De Vos
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

7.  Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.

Authors:  Folashade Adebisi Jose; Elizabeth A Garnett; Eric Vittinghoff; George D Ferry; Harland S Winter; Robert N Baldassano; Barbara S Kirschner; Stanley A Cohen; Benjamin D Gold; Oren Abramson; Melvin B Heyman
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

8.  Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers.

Authors:  Robert D Cardiff; Neil E Hubbard; Jesse A Engelberg; Robert J Munn; Claramae H Miller; Judith E Walls; Jane Q Chen; Héctor A Velásquez-García; Jose J Galvez; Katie J Bell; Laurel A Beckett; Yue-Ju Li; Alexander D Borowsky
Journal:  Lab Invest       Date:  2013-02-11       Impact factor: 5.662

9.  Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease.

Authors:  Subra Kugathasan; Robert N Baldassano; Jonathan P Bradfield; Patrick M A Sleiman; Marcin Imielinski; Stephen L Guthery; Salvatore Cucchiara; Cecilia E Kim; Edward C Frackelton; Kiran Annaiah; Joseph T Glessner; Erin Santa; Tara Willson; Andrew W Eckert; Erin Bonkowski; Julie L Shaner; Ryan M Smith; F George Otieno; Nicholas Peterson; Debra J Abrams; Rosetta M Chiavacci; Robert Grundmeier; Petar Mamula; Gitit Tomer; David A Piccoli; Dimitri S Monos; Vito Annese; Lee A Denson; Struan F A Grant; Hakon Hakonarson
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

Review 10.  Beyond Immune Cell Migration: The Emerging Role of the Sphingosine-1-phosphate Receptor S1PR4 as a Modulator of Innate Immune Cell Activation.

Authors:  Catherine Olesch; Christian Ringel; Bernhard Brüne; Andreas Weigert
Journal:  Mediators Inflamm       Date:  2017-08-07       Impact factor: 4.711

View more
  12 in total

1.  Lizhong Decoction Ameliorates Ulcerative Colitis in Mice via Regulation of Plasma and Urine Metabolic Profiling.

Authors:  Ling Wang; Jin-Hua Tao; Yi-Fan Chen; Yu-Meng Shen; Shu Jiang
Journal:  Chin J Integr Med       Date:  2021-09-29       Impact factor: 2.626

2.  Silence of S1PR4 Represses the Activation of Fibroblast-like Synoviocytes by Regulating IL-17/STAT3 Signaling Pathway.

Authors:  Pengyu Zhang; Qiang Zhang; Zhenxia Shao
Journal:  Inflammation       Date:  2022-09-06       Impact factor: 4.657

3.  The function of Sphingosine-1-phosphate receptor 2 (S1PR2) in maintaining intestinal barrier and inducing ulcerative colitis.

Authors:  Tanzhou Chen; Kaier Gu; Ruoyang Lin; Yang Liu; Yunfeng Shan
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation.

Authors:  Piming Zhao; Isaac D Liu; Jeffrey B Hodgin; Peter I Benke; Jeremy Selva; Federico Torta; Markus R Wenk; James A Endrizzi; Olivia West; Weixing Ou; Emily Tang; Denise Li-Meng Goh; Stacey Kiat-Hong Tay; Hui-Kim Yap; Alwin Loh; Nicole Weaver; Bonnie Sullivan; Austin Larson; Megan A Cooper; Khalid Alhasan; Abdullah A Alangari; Suha Salim; Evren Gumus; Karin Chen; Martin Zenker; Friedhelm Hildebrandt; Julie D Saba
Journal:  J Inherit Metab Dis       Date:  2020-05-04       Impact factor: 4.982

5.  Efficacy of AAV9-mediated SGPL1 gene transfer in a mouse model of S1P lyase insufficiency syndrome.

Authors:  Piming Zhao; Gizachew B Tassew; Joanna Y Lee; Babak Oskouian; Denise P Muñoz; Jeffrey B Hodgin; Gordon L Watson; Felicia Tang; Jen-Yeu Wang; Jinghui Luo; Yingbao Yang; Sarah King; Ronald M Krauss; Nancy Keller; Julie D Saba
Journal:  JCI Insight       Date:  2021-04-22

6.  Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

Authors:  William J Sandborn; Brian G Feagan; Stephen Hanauer; Severine Vermeire; Subrata Ghosh; Wenzhong J Liu; AnnKatrin Petersen; Lorna Charles; Vivian Huang; Keith Usiskin; Douglas C Wolf; Geert D'Haens
Journal:  J Crohns Colitis       Date:  2021-07-05       Impact factor: 9.071

7.  Serum Metabolomics Identifies Altered Bioenergetics, Signaling Cascades in Parallel with Exposome Markers in Crohn's Disease.

Authors:  Yunjia Lai; Jingchuan Xue; Chih-Wei Liu; Bei Gao; Liang Chi; Pengcheng Tu; Kun Lu; Hongyu Ru
Journal:  Molecules       Date:  2019-01-27       Impact factor: 4.411

Review 8.  Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease.

Authors:  Cristina Bauset; Laura Gisbert-Ferrándiz; Jesús Cosín-Roger
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

9.  Sphingosine-1-phosphate signal transducer and activator of transcription 3 signaling pathway contributes to baicalein-mediated inhibition of dextran sulfate sodium-induced experimental colitis in mice.

Authors:  Jing Yao; Tao Liu; Rui-Jiao Chen; Jing Liang; Jun Li; Chuan-Gong Wang
Journal:  Chin Med J (Engl)       Date:  2020-02-05       Impact factor: 2.628

10.  Membrane disruption of Fusarium oxysporum f. sp. niveum induced by myriocin from Bacillus amyloliquefaciens LZN01.

Authors:  Hengxu Wang; Zhigang Wang; Zeping Liu; Kexin Wang; Weihui Xu
Journal:  Microb Biotechnol       Date:  2020-09-20       Impact factor: 5.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.